When LCL161 was combined with paclitaxel, it degraded cIAP1 and cIAP2, which are highly expressed in NSCLC patients and confer a poor prognosis, and it resulted in the release of RIP1 from the TRADD-TRAF2-RIP1-cIAP complex, leading to the formation of the RIP1-FADD-Caspase-8 complex. Here, RIPK1 is linked to non-small cell lung carcinoma.